Physiological Study to Determine the Allergic Skin Activity After Different Skin Preparation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01628484
Recruitment Status : Completed
First Posted : June 26, 2012
Last Update Posted : November 7, 2012
Information provided by (Responsible Party):
University of Zurich

Brief Summary:

The objectives of this monocentric investigator initiated exploratory clinical trial is to optimize allergen delivery across the epidermal barrier. The cornified outer epidermal layers represent the main barrier towards entry into the viable epidermal layers. In the latter we aim to target the allergen for uptake by professional antigen presenting cells, called Langerhans cells. At the same time as little allergen as possible should be delivered to the dermis. The latter contains a high density of sensitized mast cells eliciting local reactions and also a high density of blood vessels which could lead to systemic distribution of allergen and therefore to systemic allergic reactions.

In birch pollen allergic individuals we will compare different methods of preparing the skin before application of the allergen. We will subsequently apply titrated allergen doses to the prepared skin areas to determine at which dose we start observing mast cell degranulation manifesting as hives.

This will allow for determination of the maximal tolerated allergen dose for each skin preparation method.

The skin preparation methods compared will be:

  • Single pricking with prick lancet (Entaco LTD., Redditch, Worcestershire, UK, distributed by Stallergenes®).
  • Tape stripping with conventional adhesive Tape (Tesa-film®).
  • Microchanneling with Micro Needle Patch (Micro Skin System, 3M®). The methods are strongly connected to routine diagnostics of allergies with low risk associated.

The clinical trial protocol has been submitted to the local Ethics Committee.

This comparison of skin preparation methods and the determination of the maximal tolerated allergen dose will help us to further improve epicutaneous allergen immunotherapy, which has the potential to make allergen specific immunotherapy not only considerably shorter and safer, but also more convenient for patients. Skin preparation by microneedle patches is significantly less painful than conventional injection and can be self administered. This should help improve the acceptance of allergen specific immunotherapy, as well as treatment compliance.

Condition or disease Intervention/treatment Phase
Birch Pollen Allergy Other: prick lancet Other: Tape stripping Other: Microneedle Phase 1

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparison of the Influence of Different Skin Conditions on the Allergic Skin Reactivity to Epicutaneous Allergen Exposure
Study Start Date : July 2012
Actual Primary Completion Date : September 2012
Actual Study Completion Date : September 2012

Arm Intervention/treatment
Skin Preparation Testing
The methodology of this study is an intra-individual comparison. Each study participant is treated with three skin preparation techniques (pricking, tape stripping, microneedle array)on both volar forearms.
Other: prick lancet
For the pricking skin preparation, sterile prick lancets for 1mm point skin testing will be used. They are used for allergy diagnostics in daily routine.
Other Name: Prick Lancet; Worcestershire, UK; distr. by Stallergenes®.
Other: Tape stripping
For the tape stripping in the skin preparation test conventional self adhesive tape by Tesafilm® is used.
Other Name: Tesafilm
Other: Microneedle
To induce a large number of microchannels with a maximal depth of 150µm into the cornea layer a small patch of 351 tiny needles is used, which is on the market in the US and is intended for preparing the skin for transdermal application of topical dermatology products.
Other Name: solid Microstructured Transdermal System (sMTS) by 3M®

Primary Outcome Measures :
  1. Wheal size of the immediate reaction in mm2. [ Time Frame: 15 minutes ]

Secondary Outcome Measures :
  1. Late phase response. [ Time Frame: 3 days ]
    Evaluation of late phase reaction (eczema development).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Written informed consent
  • 18-65 years old (male and female)
  • A positive clinical history for inhalant allergy presumably due to birch pollen
  • Positive screening prick test (mean wheal diameter = 3mm) to birch pollen allergen solution
  • A mean wheal size of = 7mm2 obtained in the screening prick test with histamine dihydrochloride (10mg/ml)

Exclusion criteria:

  • Impaired in understanding the nature, meaning and scope of the study or incapable of giving written informed consent
  • Participation in another clinical trial within the last 30 days and during the present study
  • Pregnancy or nursing
  • Positive skin reaction in the screening prick test to NaCl
  • Currently suffering from allergy symptoms
  • History of systemic reactions to allergens
  • Severe diseases influencing the results of the present study by discretion of the investigator
  • Immunotherapy with the allergen preparation during the past two years
  • Skin lesions and excessive hair-growth in the skin test areas
  • Treatment with prohibited concomitant medications, with the exception of medications with local effects which will not influence the results of the skin prick tests
  • Alcohol or drug abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01628484

University Hospital Zurich, Division of Dermatology
Zurich, ZH, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Principal Investigator: Thomas Kuendig, MD University Hospital Zurich, Division of Dermatology

Responsible Party: University of Zurich Identifier: NCT01628484     History of Changes
Other Study ID Numbers: SkinPrep
First Posted: June 26, 2012    Key Record Dates
Last Update Posted: November 7, 2012
Last Verified: November 2012

Additional relevant MeSH terms:
Rhinitis, Allergic, Seasonal
Rhinitis, Allergic
Nose Diseases
Respiratory Tract Diseases
Respiratory Hypersensitivity
Otorhinolaryngologic Diseases
Hypersensitivity, Immediate
Immune System Diseases